BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21869539)

  • 1. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
    Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
    Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
    Kishimoto M; Noda M
    Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
    Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
    Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
    Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
    Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
    Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
    Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
    Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
    Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
    Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    Diabetes Obes Metab; 2017 May; 19(5):744-748. PubMed ID: 28181363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
    Tatsumi F; Hashiramoto M; Hirukawa H; Kimura T; Shimoda M; Tawaramoto K; Kanda-Kimura Y; Anno T; Kawasaki F; Mune T; Matsuki M; Kaku K
    Diabetes Res Clin Pract; 2013 Jul; 101(1):35-44. PubMed ID: 23711593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.